The initial success of the copyright undeniably reshaped the pharmaceutical landscape, but investing in companies heavily reliant on unbranded versions presents a uncertain picture. While early returns were impressive, the end of patents and the emergence of less expensive alternatives have eroded sales. Consequently, a thorough evaluation of prese